Navigation Links
Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark
Date:9/2/2011

PORTOLA VALLEY, Calif., Sept. 2, 2011 /PRNewswire/ -- Spectros Corporation announced today an expansion of its distribution channels in Europe and Asia with the signing of 3 new distributors based in Korea, Switzerland, and Denmark. These groups join other distributors already selling Spectros products outside of the U.S.

"We are excited that distributors are increasingly recognizing the opportunity offered by the superior performance of the T-Stat® 303 VLS Tissue Oximeter," noted Director of Sales Elizabeth van Thillo-Rohlff. "This move accelerates our aggressive expansion into new and emerging markets in Europe and Asia."

Spectros T-Stat and Continuum Oximeters are currently the only solid-state broadband tissue oximeters on the market in the U.S. and Europe. T-Stat and Continuum compete in the ICU and operating rooms with INVOS® oximeters, marketed by Covidien, and FORE-SIGHT® oximeters, marketed by CAS Medical. In reconstructive surgery, T-Stat competes with T.Ox oximeters, marketed by ViOptix, and O2C, marketed in Europe. An expanded array of probes, including broadband NIRS Continuum® cerebral probes are currently in testing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art solid state broadband visible light (VLS) and broadband near-infrared (NIRS) spectroscopy.  The non-invasive T-Stat system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths to provide superior performance as compared to competing oximeter product lines that only use 2-4.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled "for investigational use only." T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical. T.Ox is a registered trademark of Vioptix. O2C is a trademark of LEA Medizintechnik).

For further information on the superior T-Stat and Continuum products, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spectros Corp. Deep-Monitoring Continuum Noninvasive Cerebral Oxygenation Sensors
2. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
3. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
4. Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific
5. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
6. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
7. FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products
8. TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation
9. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
10. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
11. Neogen Corporation Announces Year-End Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Atlas Genetics Ltd., the ultra-rapid Point-Of-Care ... D financing, raising $35 million from a syndicate including all ... ... the Atlas Genetics io® system has been completed with the ... in February 2016.  This new Series D equity issue will ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, a leading ... http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening ... contractors. This is the latest step in G&L’s expansion of its global clinical ...
(Date:1/21/2017)... LEAWOOD, Kan. , Jan. 20, 2017 ... pet therapeutics company focused on the licensing, development and ... Animal Pharm,s Best Company in ... was granted the award based on the ... ® (grapiprant tablets), ENTYCE ® (capromorelin oral ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow ... The report has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):